Lymphoma, T-Cell, Peripheral
Showing 1 - 25 of >10,000
Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)
Not yet recruiting
- Peripheral T Cell Lymphoma
- CHOP+selinexor+5-Azacitidine
- +2 more
- (no location specified)
Dec 29, 2022
Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)
Recruiting
- Peripheral T Cell Lymphoma
- Azacitidine Injection
- +6 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022
Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype Trial in Guangzhou (Chidamide combined with CHOP,
Recruiting
- Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
- Chidamide combined with CHOP
- Chidamide
-
Guangzhou, Guangdong, ChinaSun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Oct 7, 2022
Peripheral T-cell Lymphoma Trial in Tianjin (Lposomal mitoxantrone HCl,Cyclophosphamide,Vincristine,Etoposide and
Not yet recruiting
- Peripheral T-cell Lymphoma
- Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Insititute & Hospital
Jul 13, 2022
Peripheral T Cell Lymphoma Trial in Zhejiang (Mitoxantrone liposome?Chidamide?Azacitidine)
Recruiting
- Peripheral T Cell Lymphoma
- Mitoxantrone liposome、Chidamide、Azacitidine
-
Zhejiang, Zhejiang, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
Aug 9, 2022
Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)
Enrolling by invitation
- Peripheral T-cell Lymphoma Targeted Therapy
- Azacitidine
- +5 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023
Minimal Residual Disease in Peripheral T-cell Lymphoma
Active, not recruiting
- Peripheral T Cell Lymphoma
- Tumor biopsy
- +2 more
-
Boston, Massachusetts
- +2 more
Feb 14, 2022
T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)
Not yet recruiting
- T-Cell Lymphoma
- Brentuximab vedotin
- Pembrolizumab
- (no location specified)
Jul 22, 2022
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell
Recruiting
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- +13 more
- Brentuximab Vedotin
- Pembrolizumab
-
Chicago, IllinoisNorthwestern University
Jun 15, 2022
NK/T-cell Lymphoma Trial in Shanghai (Positron Emission Tomography/Magnetic Resonance (PET/MR))
Not yet recruiting
- NK/T-cell Lymphoma
- Positron Emission Tomography/Magnetic Resonance (PET/MR)
-
Shanghai, Shanghai, ChinaRuijin Hospital
Dec 14, 2022
Peripheral T-cell Lymphoma Trial in Shanghai (PD-1 antibody+ HDAC inhibitor)
Recruiting
- Peripheral T-cell Lymphoma
- PD-1 antibody+ HDAC inhibitor
-
Shanghai, Shanghai, ChinaDongmei Ji
Dec 3, 2021
Treatment, Peripheral T-cell Lymphoma Trial in Beijing (liposomal mitoxantrone HCl, gemcitabine, dexamethasone, and cisplatin)
Recruiting
- Treatment
- Peripheral T-cell Lymphoma
- liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
-
Beijing, China
- +4 more
Jun 28, 2022
T Cell Lymphoma Trial (Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen)
Not yet recruiting
- T Cell Lymphoma
- Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen
- (no location specified)
Mar 6, 2023
T-cell Lymphoma Trial (Tucidinostat, Azacitidine combined with CHOP)
Not yet recruiting
- T-cell Lymphoma
- Tucidinostat, Azacitidine combined with CHOP
- (no location specified)
Oct 9, 2021
Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Suzhou (Anti-PD-1 mAb, Lenalidomide, Azacitidine)
Recruiting
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Anti-PD-1 monoclonal antibody
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 21, 2021
T-Cell Lymphoma Trial (Brentuximab vedotin)
Not yet recruiting
- T-Cell Lymphoma
- Brentuximab vedotin
- (no location specified)
Jun 30, 2022
Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)
Not yet recruiting
- Extranodal NK/T-cell Lymphoma
- Sugemalimab
- +4 more
- (no location specified)
Jan 17, 2023
Peripheral T-Cell Lymphoma Trial in Zhengzhou (Parsaclisib, Chidamide)
Not yet recruiting
- Peripheral T-Cell Lymphoma
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Dec 26, 2021
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in London (Avelumab)
Completed
- T-Cell Lymphoma Relapsed
- T-Cell Lymphoma Refractory
-
London, United KingdomUniversity College London Hospital
Oct 1, 2021
Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)
Recruiting
- Peripheral T Cell Lymphoma
- ATLCAR.CD30 T cells
- +3 more
-
Chapel Hill, North Carolina
- +1 more
Mar 4, 2022
Extranodal NK/T Cell Lymphoma Trial in Nanjing (Pegaspargase(P-GOD), Pegaspargase(PEMD))
Not yet recruiting
- Extranodal NK/T Cell Lymphoma
-
Nanjing, Jiangsu, ChinaHematological Department, People's Hospital of Jiangsu Province
Jun 16, 2022
T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory Trial in United States (LB1901)
Active, not recruiting
- T-Cell Lymphoma
- +4 more
- LB1901
-
Rochester, Minnesota
- +3 more
Feb 15, 2022
T-cell Lymphoma, Virus, Intravenous Injection Trial (Oncolytic Virus Injection(RT-01))
Not yet recruiting
- T-cell Lymphoma
- +2 more
- Oncolytic Virus Injection(RT-01)
- (no location specified)
May 18, 2022
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma
Recruiting
- Anaplastic Large Cell Lymphoma
- +19 more
- Pembrolizumab
- Pralatrexate
-
Duarte, California
- +2 more
Aug 15, 2022